EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab

Chad A Reade1, Apar Kishor Ganti1,21Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 2Section of Oncology-Hematology, Department of internal Medicine, VA Medical Center, Omaha, NE, USAAbstract: Chemotherapy alone has limited ability to significantly improve sur...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chad A Reade, Apar Kishor Ganti
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/8d4fb8e88384411c8632dee95a7350c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:8d4fb8e88384411c8632dee95a7350c3
record_format	dspace
spelling	oai:doaj.org-article:8d4fb8e88384411c8632dee95a7350c32021-12-02T08:15:15ZEGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab1177-54751177-5491https://doaj.org/article/8d4fb8e88384411c8632dee95a7350c32009-05-01T00:00:00Zhttp://www.dovepress.com/egfr-targeted-therapy-in-non-small-cell-lung-cancer-potential-role-of--a3119https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Chad A Reade1, Apar Kishor Ganti1,21Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 2Section of Oncology-Hematology, Department of internal Medicine, VA Medical Center, Omaha, NE, USAAbstract: Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Cetuximab is a human &ndash; mouse chimeric immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. Cetuximab is currently the focus of intense investigation in various patient populations with NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future directions with this agent.Keywords: non-small cell lung cancer, EGFR, cetuximab, monoclonal antibodies Chad A ReadeApar Kishor GantiDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2009, Iss default, Pp 215-224 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Chad A Reade Apar Kishor Ganti EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
description	Chad A Reade1, Apar Kishor Ganti1,21Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA; 2Section of Oncology-Hematology, Department of internal Medicine, VA Medical Center, Omaha, NE, USAAbstract: Chemotherapy alone has limited ability to significantly improve survival in non-small lung cancer (NSCLC) beyond what has already been achieved. The epidermal growth factor (EGF) pathway plays a vital role in the pathogenesis and progression of NSCLC. Two classes of drugs inhibit the EGF receptor (EGFR) pathway: small molecules that inhibit the intracellular tyrosine kinase activity of the receptor, and monoclonal antibodies that target the extracellular domain in the ligand-binding region. Cetuximab is a human &ndash; mouse chimeric immunoglobulin G1 class monoclonal antibody directed against EGFR. Preclinical studies with cetuximab suggested that there was inhibition of growth of human NSCLC cell lines. Cetuximab is currently the focus of intense investigation in various patient populations with NSCLC. This review focuses on clinical trials of cetuximab in NSCLC and identifies future directions with this agent.Keywords: non-small cell lung cancer, EGFR, cetuximab, monoclonal antibodies
format	article
author	Chad A Reade Apar Kishor Ganti
author_facet	Chad A Reade Apar Kishor Ganti
author_sort	Chad A Reade
title	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
title_short	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
title_full	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
title_fullStr	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
title_full_unstemmed	EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
title_sort	egfr targeted therapy in non-small cell lung cancer: potential role of cetuximab
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/8d4fb8e88384411c8632dee95a7350c3
work_keys_str_mv	AT chadareade egfrtargetedtherapyinnonsmallcelllungcancerpotentialroleofcetuximab AT aparkishorganti egfrtargetedtherapyinnonsmallcelllungcancerpotentialroleofcetuximab
_version_	1718398612626472960

EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab

Ejemplares similares